Literature DB >> 16525405

Bayh-Dole: if we knew then what we know now.

Sara Boettiger1, Alan B Bennett.   

Abstract

Entities:  

Mesh:

Year:  2006        PMID: 16525405     DOI: 10.1038/nbt0306-320

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  7 in total

1.  The role of funding and policies on innovation in cancer drug development.

Authors:  P Kanavos; R Sullivan; G Lewison; W Schurer; S Eckhouse; Z Vlachopioti
Journal:  Ecancermedicalscience       Date:  2010-02-03

Review 2.  Licensing biotech intellectual property in university-industry partnerships.

Authors:  Vladimir Drozdoff; Daryl Fairbairn
Journal:  Cold Spring Harb Perspect Med       Date:  2015-01-20       Impact factor: 6.915

3.  Bridging the Valley of Death of therapeutics for neurodegeneration.

Authors:  Steven Finkbeiner
Journal:  Nat Med       Date:  2010-09-21       Impact factor: 53.440

4.  Barriers to investigator-initiated deep brain stimulation and device research.

Authors:  Michael L Kelly; Donald Malone; Michael S Okun; Joan Booth; Andre G Machado
Journal:  Neurology       Date:  2014-03-26       Impact factor: 9.910

5.  Impact of gene patents and licensing practices on access to genetic testing for long QT syndrome.

Authors:  Misha Angrist; Subhashini Chandrasekharan; Christopher Heaney; Robert Cook-Deegan
Journal:  Genet Med       Date:  2010-04       Impact factor: 8.864

6.  Policy challenges for cancer research: a call to arms.

Authors:  R Sullivan
Journal:  Ecancermedicalscience       Date:  2007-09-18

Review 7.  What is the future of peer review? Why is there fraud in science? Is plagiarism out of control? Why do scientists do bad things? Is it all a case of: "all that is necessary for the triumph of evil is that good men do nothing"?

Authors:  Chris R Triggle; David J Triggle
Journal:  Vasc Health Risk Manag       Date:  2007
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.